MA22051A1 - Procede d'obtention d'une formulation pharmaceutique - Google Patents

Procede d'obtention d'une formulation pharmaceutique

Info

Publication number
MA22051A1
MA22051A1 MA22324A MA22324A MA22051A1 MA 22051 A1 MA22051 A1 MA 22051A1 MA 22324 A MA22324 A MA 22324A MA 22324 A MA22324 A MA 22324A MA 22051 A1 MA22051 A1 MA 22051A1
Authority
MA
Morocco
Prior art keywords
obtaining
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
MA22324A
Other languages
English (en)
Inventor
J Goodall A
O Yeboah J
A Griffiths H
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of MA22051A1 publication Critical patent/MA22051A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA22324A 1990-01-26 1991-01-24 Procede d'obtention d'une formulation pharmaceutique MA22051A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909001886A GB9001886D0 (en) 1990-01-26 1990-01-26 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
MA22051A1 true MA22051A1 (fr) 1991-10-01

Family

ID=10669997

Family Applications (1)

Application Number Title Priority Date Filing Date
MA22324A MA22051A1 (fr) 1990-01-26 1991-01-24 Procede d'obtention d'une formulation pharmaceutique

Country Status (29)

Country Link
EP (1) EP0511991B1 (fr)
JP (1) JP2545317B2 (fr)
KR (1) KR0170414B1 (fr)
CN (1) CN1056058C (fr)
AP (1) AP197A (fr)
AT (1) ATE142880T1 (fr)
AU (1) AU643975B2 (fr)
CA (1) CA2074503C (fr)
CY (2) CY1984A (fr)
DE (1) DE69122229T2 (fr)
DK (1) DK0511991T3 (fr)
ES (1) ES2092559T3 (fr)
FI (1) FI101600B (fr)
GB (1) GB9001886D0 (fr)
GR (1) GR3021385T3 (fr)
HK (1) HK218996A (fr)
HU (1) HU215842B (fr)
IE (1) IE910249A1 (fr)
IL (1) IL97008A (fr)
LU (1) LU90110I2 (fr)
MA (1) MA22051A1 (fr)
MY (1) MY110074A (fr)
PL (1) PL166678B1 (fr)
PT (1) PT96563B (fr)
SA (1) SA91110341B1 (fr)
SG (1) SG49144A1 (fr)
TW (1) TW307687B (fr)
WO (1) WO1991011187A1 (fr)
ZA (1) ZA91525B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114939D0 (en) * 1991-07-11 1991-08-28 Smithkline Beecham Plc Pharmaceutical formulation
US6124304A (en) * 1993-10-05 2000-09-26 Smithkline Beecham Plc Penciclovir for the treatment of zoster associated pain
GB9326177D0 (en) * 1993-12-22 1994-02-23 Smithkline Beecham Plc Pharmaceuticals
GB9601544D0 (en) * 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
US7223387B2 (en) 1998-11-18 2007-05-29 Medivir Ab Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
WO2017029298A1 (fr) 2015-08-17 2017-02-23 Sanovel Ilac Sanayi Ve Ticaret A.S. Composition antivirale topique
WO2019195802A1 (fr) 2018-04-05 2019-10-10 Bausch Health Ireland Limited Systèmes de distribution d'émulsion polymère

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
GB2080106B (en) * 1980-07-18 1984-03-07 Weelcome Foundation Ltd Acyclovin preparations
KR830005852A (ko) * 1980-07-18 1983-09-14 미첼 페터 잭슨 피부와 점막의 비루스 감염치료에 적합한 국소치료제의 제조방법
EP0095813A3 (fr) * 1982-06-01 1985-05-08 THE PROCTER & GAMBLE COMPANY Compositions pharmaceutiques topiques pénétrantes contenant la 9-(2-hydroxyéthoxyméthyl)-guanine
EP0141927B1 (fr) * 1983-08-18 1991-10-30 Beecham Group Plc Dérivés de guanine antiviraux
IL73682A (en) * 1983-12-20 1991-08-16 Medivir Ab Antiviral pharmaceutical compositions containing 9-hydroxy aliphatic derivatives of guanine,some new such derivatives and process for their preparation
DE3571810D1 (en) * 1984-01-26 1989-08-31 Merck & Co Inc Substituted butyl guanines and their utilization in antiviral compositions
DE3671227D1 (de) * 1985-07-27 1990-06-21 Beecham Group Plc 9-substituierte guaninmonohydrate.

Also Published As

Publication number Publication date
IL97008A (en) 1995-05-26
AP9000236A0 (en) 1991-01-31
PL166678B1 (pl) 1995-06-30
ES2092559T3 (es) 1996-12-01
WO1991011187A1 (fr) 1991-08-08
CN1056058C (zh) 2000-09-06
CY1999020I2 (en) 2009-11-04
EP0511991A1 (fr) 1992-11-11
KR920703060A (ko) 1992-12-17
KR0170414B1 (ko) 1999-02-18
HU9202431D0 (en) 1992-10-28
GR3021385T3 (en) 1997-01-31
JPH05503695A (ja) 1993-06-17
HU215842B (hu) 2001-02-28
CA2074503C (fr) 1999-12-14
ZA91525B (en) 1992-02-26
FI923371A0 (fi) 1992-07-24
FI923371A (fi) 1992-07-24
TW307687B (fr) 1997-06-11
IL97008A0 (en) 1992-03-29
PT96563B (pt) 1998-07-31
SG49144A1 (en) 1998-05-18
CA2074503A1 (fr) 1991-07-27
LU90110I2 (fr) 1997-09-25
JP2545317B2 (ja) 1996-10-16
DK0511991T3 (da) 1996-11-11
EP0511991B1 (fr) 1996-09-18
DE69122229T2 (de) 1997-03-06
ATE142880T1 (de) 1996-10-15
DE69122229D1 (de) 1996-10-24
FI101600B1 (fi) 1998-07-31
MY110074A (en) 1997-12-31
HK218996A (en) 1997-01-03
GB9001886D0 (en) 1990-03-28
AU7155891A (en) 1991-08-21
CN1053547A (zh) 1991-08-07
FI101600B (fi) 1998-07-31
HUT62472A (en) 1993-05-28
IE910249A1 (en) 1991-07-31
CY1984A (en) 1997-09-05
AU643975B2 (en) 1993-12-02
PT96563A (pt) 1991-10-15
AP197A (en) 1992-06-30
SA91110341B1 (ar) 2004-05-25

Similar Documents

Publication Publication Date Title
MA22819A1 (fr) Procede de preparation d'un nouveau produit pharmaceutique.
MA22894A1 (fr) Procede de preparation d'un vaccin.
FR11C0007I2 (fr) Composition pharmaceutique stabilisee a l'aide d'un agent de base
MA22668A1 (fr) Procede de preparation d'oxamides .
NO177038C (no) Fremgangsmåte for fremstilling av et farmasöytisk doseringssystem
MA22481A1 (fr) Procede de preparation d'acides imidazolyl - alcenoiques .
FR2734483B1 (fr) Forme d'administration pharmaceutique comprenant de l'oxybutynine
PT87422A (pt) Procede de preparation d'une forme de dosage solide pharmaceutque a base de cimetidine
FR2621785B1 (fr) Procede de preparation d'un roux
FR2689887B1 (fr) Procede de preparation d'un derive de biphenyle.
MA22443A1 (fr) Procede de preparation d'une composition pharmaceutique .
OA08192A (fr) Nouveau procédé d'obtention de formes pharmaceutiques à libération prolongée.
MA22051A1 (fr) Procede d'obtention d'une formulation pharmaceutique
MA22243A1 (fr) Procede d'obtention d'agar-agar a solubilisation rapide
FR2626088B1 (fr) Procede d'obtention d'une composition de couchage photographique
FR2635550B1 (fr) Procede de surelevation d'immeubles
FR2630735B1 (fr) Procede de preparations d'halogenophenols
FR2658786B1 (fr) Procede d'obtention d'un conditionnement et conditionnement.
MA18628A1 (fr) Procede d'obtention de nouvelles compositions pharmaceutiques a base d'aryltrigluoroethanol
FR2644161B1 (fr) Procede de preparation d'amides n-arylsubstitues
FR2668707B1 (fr) Procede de preparation d'une composition pharmaceutique.
FR2664279B1 (fr) Procede d'obtention de kappa carraghenanes.
FR2581060B1 (fr) Procede industriel d'obtention du midalcipran
FR2643647B1 (fr) Procede microbiologique d'obtention de methylcetones
FR2578743B3 (fr) Procede de fabrication d'une preparation medicamenteuse a base de substance mesenchymateuse du type microsepteurs